Cha Biotech Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Umbilical cord-derived adherent stem cells, preparation method therefor, and use thereof (US 11,690,877) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due May 19, 2027The maintenance fee for Postnatal adherent cells and preparation method therefor (US 10,479,978) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,919,318 | Process for isolating vascular endothelial cells from embryoid bodies differentiated from embryonc stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,921,107 | Method for Differentiating Human Neural Progenitor Cells into Dopaminergic Neurons, and Medium for Differentiation Thereof In force · High confidence | In force | High confidence | |
| US 11,351,194 | Method for proliferating neural progenitor cells and composition for treating neurological diseases containing proliferated neural progenitor cells In force · From the USPTO record | In force | From the USPTO record | |
| US 10,479,978 | Postnatal adherent cells and preparation method therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 12,478,646 | Umbilical cord-derived adherent stem cells, preparation method therefor, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,690,877 | Umbilical cord-derived adherent stem cells, preparation method therefor, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,091,679 | Storage Method and Banking System of NT Cell In force · High confidence | In force | High confidence | |
| US 12,319,936 | Natural killer cells exhibiting increased anticancer activity and immunotherapeutic use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,371,664 | Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 9: 1 patent in force now held by others · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 6 no status recorded